{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:29:19Z","timestamp":1791919759557,"version":"4.3.4"},"reference-count":107,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1053\/j.seminoncol.2012.11.003","type":"journal-article","created":{"date-parts":[[2013,2,5]],"date-time":"2013-02-05T01:18:46Z","timestamp":1360027126000},"page":"84-99","source":"Crossref","is-referenced-by-count":31,"title":["Systemic Therapeutic Options for Carcinoid"],"prefix":"10.1053","volume":"40","author":[{"given":"Marianne","family":"Pavel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irvin","family":"Modlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2012.11.003_bib1","first-page":"426","article-title":"Karzinoide Tumoren des D\u00fcnndarmes","volume":"1","author":"Oberndorfer","year":"1907","journal-title":"Fr Zeitschrift Pathol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib2","first-page":"76","article-title":"Sur une nouvelle esp\u00e9ce cellulaire dans les glandes de Lieberk\u00fchn","volume":"60","author":"Ciaccio","year":"1906","journal-title":"CR Soc Biol Paris"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib3","first-page":"59","article-title":"La glande endocrine de l'intestin chez l'homme","volume":"158","author":"Masson","year":"1914","journal-title":"CR Acad Sci"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(63)90951-6","article-title":"The classification of carcinoid tumours","volume":"1","author":"Williams","year":"1963","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib5","series-title":"WHO classification of tumours of the digestive system","author":"Bosman","year":"2010"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib6","series-title":"World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart","author":"Travis","year":"2004"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib7","series-title":"Oberndorfer centennial","author":"Modlin","year":"2008"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib8","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib10","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1002\/cncr.24498","article-title":"Pulmonary neuroendocrine\/carcinoid tumors: a review article","volume":"115","author":"Bertino","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib11","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1378\/chest.119.6.1647","article-title":"Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature","volume":"119","author":"Fink","year":"2001","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.gtc.2010.08.013","article-title":"New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors","volume":"39","author":"Lawrence","year":"2010","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib13","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2010.33.2056","article-title":"Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting","volume":"29","author":"Kulke","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1677\/ERC-08-0301","article-title":"Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma","volume":"16","author":"Durante","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/erc.1.01017","article-title":"Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization","volume":"12","author":"Panzuto","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","article-title":"ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary","volume":"95","author":"Pavel","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1159\/000197899","article-title":"Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut","volume":"89","author":"Strosberg","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/ERC-08-0017","article-title":"Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours","volume":"15","author":"Pape","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cncr.23549","article-title":"Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors","volume":"113","author":"Pape","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib20","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJM198312153092406","article-title":"Somatostatin","volume":"309","author":"Reichlin","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000111034","article-title":"Consensus guidelines for the management of patients with digestive neuroendocrine tumors\u2014well-differentiated jejunal-ileal tumor\/carcinoma","volume":"87","author":"Eriksson","year":"2008","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","article-title":"The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum","volume":"39","author":"Boudreaux","year":"2010","journal-title":"Pancreas"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib23","first-page":"145","article-title":"Neuroendocrine tumors","volume":"21","author":"Plockinger","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib24","first-page":"3455","article-title":"Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization","volume":"54","author":"Reubi","year":"1994","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib25","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/bjc.1998.101","article-title":"Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours","volume":"77","author":"Nilsson","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome","volume":"315","author":"Kvols","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000082875","article-title":"Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide","volume":"80","author":"Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib29","first-page":"4127","article-title":"High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors","volume":"29","author":"Chadha","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib30","first-page":"93","article-title":"Dose escalation of octreotide LAR is safe and effective in patients with advanced gastrointestinal neuroendocrine tumours for control of symptoms and tumor progression","volume":"74","author":"Verslype","year":"2011","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib31","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000007693","article-title":"Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors","volume":"60","author":"Faiss","year":"1999","journal-title":"Digestion"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib32","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"Susini","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1530\/EJE-08-0420","article-title":"Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours","volume":"159","author":"Grozinsky-Glasberg","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib34","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib35","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib36","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1111\/j.1572-0241.2000.03210.x","article-title":"The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors","volume":"95","author":"Ducreux","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib37","unstructured":"NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Cancer Netw. Version 1.2012."},{"key":"10.1053\/j.seminoncol.2012.11.003_bib38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1677\/ERC-07-0251","article-title":"Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs","volume":"15","author":"Campana","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib39","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/MEG.0b013e328220eae0","article-title":"Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue","volume":"19","author":"Manfredi","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib40","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJM200008243430805","article-title":"Treatment of type II gastric carcinoid tumors with somatostatin analogues","volume":"343","author":"Tomassetti","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib41","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/00365521.2010.539255","article-title":"Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids","volume":"46","author":"Jianu","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib42","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib43","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","article-title":"90Y-edotreotide for metastatic carcinoid refractory to octreotide","volume":"28","author":"Bushnell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib44","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib45","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00277-011-1345-6","article-title":"Secondary haematological malignancies after radioimmunotherapy","volume":"91","author":"Gigli","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib46","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s00259-009-1282-y","article-title":"Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues","volume":"37","author":"Rolleman","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib47","first-page":"35","article-title":"The action of interferon alpha on human carcinoid tumours","volume":"3","author":"Oberg","year":"1992","journal-title":"Semin Cancer Biol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib48","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2012.11.003_bib49","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000051862","article-title":"Interferon in the management of neuroendocrine GEP-tumors: a review","volume":"62","author":"Oberg","year":"2000","journal-title":"Digestion"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib50","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/02841869109092411","article-title":"The role of interferons in the management of carcinoid tumors","volume":"30","author":"Oberg","year":"1991","journal-title":"Acta Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/jir.2006.26.8","article-title":"Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas","volume":"26","author":"Pavel","year":"2006","journal-title":"J Interferon Cytokine Res"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib52","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","article-title":"Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2012.11.003_bib53","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000201403","article-title":"Interferon-alpha versus somatostatin or the combination of both in gastroenteropancreatic tumours","volume":"57","author":"\u00d6berg","year":"1996","journal-title":"Digestion"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib54","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib55","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib56","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours","volume":"90","author":"Janson","year":"2003","journal-title":"Br J Surg"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib57","first-page":"1381","article-title":"Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors","volume":"94","author":"Frank","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841869309083916","article-title":"Long-term management of the carcinoid syndrome","volume":"32","author":"Janson","year":"1993","journal-title":"Acta Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib59","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1677\/ERC-09-0104","article-title":"Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710","volume":"16","author":"Dahan","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib60","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1023\/A:1012569909313","article-title":"Experience in treatment of metastatic pulmonary carcinoid tumors","volume":"12","author":"Granberg","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib61","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","article-title":"A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas","volume":"95","author":"Duran","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib62","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","article-title":"Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1053\/j.seminoncol.2012.11.003_bib63","article-title":"Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET)","volume":"30","author":"Yao","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1677\/ERC-10-0126","article-title":"mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours","volume":"18","author":"Kasajima","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib65","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00280-009-1094-6","article-title":"Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors","volume":"65","author":"Shida","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib66","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/sj.bjc.6602245","article-title":"Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression","volume":"92","author":"Couvelard","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib67","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development","volume":"6","author":"Faivre","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib68","article-title":"Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787\/ZK222584 (PTK\/ZK) in patients with advanced neuroendocrine carcinomas (NEC)","volume":"26","author":"Pavel","year":"2008","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib69","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-007-0521-9","article-title":"Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors","volume":"61","author":"Varker","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib70","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2006.05.6762","article-title":"Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib71","first-page":"9","article-title":"Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors","volume":"9","author":"Chan","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib72","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00280-010-1478-7","article-title":"A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors","volume":"68","author":"Kulke","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl 15S","key":"10.1053\/j.seminoncol.2012.11.003_bib73","article-title":"A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors","volume":"28","author":"Kunz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15S","key":"10.1053\/j.seminoncol.2012.11.003_bib74","article-title":"Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker","volume":"28","author":"Yao","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib75","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl 18S","key":"10.1053\/j.seminoncol.2012.11.003_bib76","article-title":"MCO44h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumours (NET): a phase II consortium (P2C) study","volume":"25","author":"Hobday","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1053\/j.seminoncol.2012.11.003_bib77","article-title":"Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: a phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801)","volume":"29","author":"Castellano","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib78","first-page":"327","article-title":"Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome","volume":"2","author":"Moertel","year":"1979","journal-title":"Cancer Clin Trials"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib79","first-page":"1459","article-title":"Phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome","volume":"70","author":"Moertel","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib80","doi-asserted-by":"crossref","first-page":"302","DOI":"10.7326\/0003-4819-120-4-199402150-00008","article-title":"The management of patients with advanced carcinoid tumors and islet cell carcinomas","volume":"120","author":"Moertel","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib81","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","article-title":"Phase II\/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281","volume":"23","author":"Sun","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib82","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/sj.bjc.6605618","article-title":"Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours","volume":"102","author":"Turner","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib83","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib84","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s10620-006-8001-3","article-title":"A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors","volume":"51","author":"Kulke","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib85","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.1984.2.11.1255","article-title":"Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor","volume":"2","author":"Engstrom","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib86","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1677\/ERC-09-0319","article-title":"Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas","volume":"18","author":"Hentic","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl","key":"10.1053\/j.seminoncol.2012.11.003_bib87","article-title":"Treatment of advanced neuroendocrine tumors: results of the UKINETS and NCRI randomized phase II NET01 trial","volume":"30","author":"Corrie","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib88","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/1471-2407-9-388","article-title":"Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas","volume":"9","author":"Brizzi","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib89","first-page":"627","article-title":"Treatment of metastasized midgut carcinoids with dacarbazine","volume":"90","author":"Ritzel","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib90","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00000421-199806000-00005","article-title":"Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial","volume":"21","author":"Ollivier","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib91","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/oxfordjournals.annonc.a059049","article-title":"A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours","volume":"6","author":"Di Bartolomeo","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib92","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<372::AID-CNCR23>3.0.CO;2-P","article-title":"5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors","volume":"83","author":"Bajetta","year":"1998","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib93","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib94","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib95","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000225389","article-title":"Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors","volume":"90","author":"Maire","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib96","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib97","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00280-006-0306-6","article-title":"Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?","volume":"59","author":"Bajetta","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib98","first-page":"117","article-title":"Sustained response to FOLFOX and bevacizumab in metastatic bronchial carcinoid\u2014a case report and review of the literature","volume":"2","author":"Akunyili","year":"2011","journal-title":"J Gastrointest Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib99","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1002\/cncr.24384","article-title":"Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience","volume":"115","author":"Cassier","year":"2009","journal-title":"Cancer"},{"issue":"18S","key":"10.1053\/j.seminoncol.2012.11.003_bib100","article-title":"Oxaliplatin plus 5-fluorouracil\/folinic acid as palliative treatment for progressive malignant gastrointestinal neuroendocrine carcinomas","volume":"24","author":"Pape","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1053\/j.seminoncol.2012.11.003_bib101","article-title":"Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors","volume":"26","author":"Venook","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib102","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/PAS.0b013e31818d7d8b","article-title":"Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors","volume":"33","author":"Srivastava","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib103","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00428-011-1118-6","article-title":"Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2","volume":"459","author":"Hermann","year":"2011","journal-title":"Virchows Arch"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib104","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-009-1205-y","article-title":"Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET\/CT","volume":"37","author":"Prasad","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000265561","article-title":"Impact of multiphase 68Ga-DOTATOC-PET\/CT on therapy management in patients with neuroendocrine tumors","volume":"91","author":"Ruf","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib106","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/cncr.25855","article-title":"Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome","volume":"117","author":"Jann","year":"2011","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.003_bib107","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2011.40.3824","article-title":"The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs","volume":"30","author":"Niraula","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775412002023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775412002023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T13:34:57Z","timestamp":1714916097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775412002023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0093775412002023"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2012.11.003","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}